摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

反式-2-烯-十七酸 | 26265-99-6

中文名称
反式-2-烯-十七酸
中文别名
十七碳烯酸
英文名称
heptadec-2E-enoic acid
英文别名
heptadec-2-enoic acid;Heptadecen-(1)-carbonsaeure;Heptadec-2-ensaeure;8Z-Heptadecenoic acid;heptadecenoic acid;trans-Δ2-Heptadecensaeure-(1);2-Heptadecenoic acid;(E)-heptadec-2-enoic acid
反式-2-烯-十七酸化学式
CAS
26265-99-6
化学式
C17H32O2
mdl
——
分子量
268.44
InChiKey
GEHPRJRWZDWFBJ-FOCLMDBBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 稳定性/保质期:
    - 存在于烤烟烟叶和香料烟烟叶中。 - 原文献未确定烯键的具体位置。

计算性质

  • 辛醇/水分配系数(LogP):
    7.5
  • 重原子数:
    19
  • 可旋转键数:
    14
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

制备方法与用途

制备方法
  • 烟草: OR,26; FC,50; FC,13。
合成制备方法
  • 烟草: OR,26;FC,50;FC,13。
用途简介

暂无相关信息。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    反式-2-烯-十七酸 生成 heptadec-2-enoic acid-(4-bromo-anilide)
    参考文献:
    名称:
    The Synthesis of 2-Pentadecenoic and 2-Heptadecenoic Acids
    摘要:
    DOI:
    10.1021/ja01849a078
  • 作为产物:
    描述:
    参考文献:
    名称:
    Grimmer,G.; Hildebrandt,A., Justus Liebigs Annalen der Chemie, 1965, vol. 685, p. 154 - 160
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
    申请人:UNIV CALIFORNIA
    公开号:WO2013078430A1
    公开(公告)日:2013-05-30
    The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.
    本发明提供了用于抑制N-酰乙醇胺酸酰胺酶(NAAA)的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺(PEA)和油酰乙醇胺(OEA)水平的方法,这两种物质是NAAA的底物,在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。
  • Structural confirmation of the dihydrosphinganine and fatty acid constituents of the dental pathogen Porphyromonas gingivalis
    作者:JiYoung Mun、Amber Onorato、Frank C. Nichols、Martha D. Morton、Abdullah I. Saleh、Morgan Welzel、Michael B. Smith
    DOI:10.1039/b712707c
    日期:——
    Porphyromonas gingivalis, a recognized periodontal pathogen, is a source of sphinganine bases, fatty acids, free ceramides as well as complex lipids that potentiate interleukin-1b-mediated secretory responses in gingival fibroblasts. The purpose of this study is the structural verification of the sphinganine bases and fatty acids that had been proposed as major components of the complex lipids found in P. gingivalis. The putative C17, C18, and C19 sphinganine bases were prepared from Garner's aldehyde (1) or from a protected serine Weinreb's amide (2). We confirmed that isobranched sphinganine bases are the major structural feature of the ceramides observed from P. gingivalis. We also prepared a C17 unsaturated fatty acid, along with an isobranched C17 3-hydroxy fatty acid, and determined that the major component of the active lipids was the latter.
    牙龈卟啉单胞菌(Porphyromonas gingivalis),一种公认的牙周病原体,是产生丝氨酸基础、脂肪酸、游离神经酰胺以及增强牙龈成纤维细胞中白细胞介素-1β介导的分泌反应的复杂脂质的来源。本研究旨在对先前提出的作为牙龈卟啉单胞菌中发现的复杂脂质主要成分的丝氨酸基础和脂肪酸进行结构验证。假定的C17、C18和C19丝氨酸基础从Garner醛(1)或从保护的丝氨酸Weinreb酰胺(2)中制备。我们确认等分支丝氨酸基础是来自牙龈卟啉单胞菌的神经酰胺观察到的主要结构特征。我们还制备了C17不饱和脂肪酸和一个等分支的C17 3-羟基脂肪酸,并确定活性脂质的主要成分是后者。
  • SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF
    申请人:The United States of America, as represented by the Secretary, Department of Health and Human Serv
    公开号:US20130302247A1
    公开(公告)日:2013-11-14
    There are provided, inter alia, methods for diagnosis of the extent of neuroinflammation in a subject. The methods include administering an 18 F-labeled arachidonic acid to a subject in need thereof, obtaining a positron emission tomography (PET) scan of the subject, and determine the extent of neuroinflammation from the PET scan. There are provided, inter alia, methods of synthesis of reagents useful for the production of an 18 F-labeled arachidonic acid.
    提供了诊断受试者神经炎症程度的方法,其中包括向需要的受试者施用18F标记的花生四烯酸,获取受试者的正电子发射断层扫描(PET扫描),并根据PET扫描确定神经炎症的程度。此外,还提供了合成试剂的方法,用于生产18F标记的花生四烯酸。
  • METHOD OF MAKING FATTY ACID N-ACYLALKANOLAMINES
    申请人:Iowa State University Research Foundation, Inc.
    公开号:US20130303795A1
    公开(公告)日:2013-11-14
    The present invention relates to methods for making a fatty acid N-acylalkanolamine having the formula: One of the methods comprises the steps of providing a vinyl ester of a fatty acid having the formula: providing a primary or secondary alkanolamine having the formula: NHR 1 R 2 ; and reacting the vinyl ester of the fatty acid with the alkanolamine under conditions effective to form the fatty acid N-acylalkanolamine. The other method comprises the steps of providing a fatty acid; purifying the fatty acid; providing a primary or secondary alkanolamine having the formula: NHR 1 R 2 ; reacting the fatty acid with the alkanolamine under conditions effective to form the fatty acid N-acylalkanolamine; and purifying the formed fatty acid N-acylalkanolamine.
    本发明涉及制备具有以下结构式的脂肪酸N-酰基醇胺的方法: 其中一种方法包括以下步骤:提供具有以下结构式的脂肪酸的乙烯酯;提供具有以下结构式的一级或二级烷基胺:NHR1R2;并在有效条件下使脂肪酸的乙烯酯与烷基胺反应,形成脂肪酸N-酰基醇胺。另一种方法包括以下步骤:提供脂肪酸;纯化脂肪酸;提供具有以下结构式的一级或二级烷基胺:NHR1R2;在有效条件下使脂肪酸与烷基胺反应,形成脂肪酸N-酰基醇胺;并纯化形成的脂肪酸N-酰基醇胺。
  • Substituted Heterocyclic Derivative, Preparation Method And Use Thereof
    申请人:Xiamen University
    公开号:US20170334896A1
    公开(公告)日:2017-11-23
    The invention provides a compound as shown by Formula I having an enzyme activity which can inhibit endocannabinoid hydrolases NAAA and/or FAAH, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a preparation method and a use of the compound.
    本发明提供一种具有酶活性的化合物,其化学式如下(I),能够抑制内源性大麻素水解酶NAAA和/或FAAH,或其药学上可接受的盐、水合物或溶剂化物,以及该化合物的制备方法和用途。
查看更多